Epigenetic Modifications and Their Role in Type 1 Diabetes Development: A Review

Type 1 Diabetes Mellitus (T1DM) is a multifactorial autoimmune disease marked by pancreatic β-cell destruction and insulin deficiency. Its pathogenesis involves genetic predisposition, environmental exposures, and epigenetic modifications. This review examines how epigenetic mechanisms, including DNA methylation, histone modifications, and noncoding RNAs, contribute to T1DM and their potential as biomarkers and therapeutic targets.

A comprehensive literature review was conducted using PubMed, Scopus, Web of Knowledge, and Google Scholar. Studies on DNA methylation, histone modifications, and noncoding RNA expression in T1DM patients and experimental models were analyzed to identify mechanisms linking epigenetic mechanisms to disease progression. Results Epigenetic alterations, including abnormal DNA methylation, histone modifications, and dysregulated non-coding RNAs, play central roles in immune imbalance and β-cell dysfunction. DNA methylation affects genes involved in immune regulation, insulin synthesis, and β-cell survival. Non-coding RNAs regulate transcriptional and inflammatory pathways, while histone modifications alter chromatin accessibility, further contributing to β-cell loss.

Epigenetic mechanisms mediate interactions between genetic risk and environmental triggers, shaping autoimmunity and disease heterogeneity. These findings underscore their relevance for early detection and targeted interventions in T1DM.

Epigenetic changes form a critical link between genetics, environment, and immune dysfunction in T1DM. By regulating immune responses and β-cell integrity, they drive disease onset and progression. Their study provides opportunities for predictive biomarkers and innovative therapies aimed at reprogramming epigenetic pathways to restore immune tolerance and preserve β-cell function.